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Renal cell carcinoma is the most common primary renal neoplasm in adults. Although renal cell carcinoma is known 
to spread to unusual sites, the ampulla of Vater is considered a rare site for metastasis. Here we present a case 
of renal cell carcinoma metastasized to the ampulla of Vater along with literature review. A 62-year-old Korean male 
had a history of hypertension and right-sided renal cell carcinoma diagnosed in September 2004, for which he under-
went right radical nephrectomy in October 2004. The patient eventually underwent laparoscopic pylorus-preserving total 
pancreaticoduodenectomy in January 2017. The surgery was successful without postoperative complications. Previous 
studies have shown that surgical resection for solitary metastases of renal cell carcinoma can provide favorable survival 
rates. Our case report provides evidence that pancreaticoduodenectomy may be a treatment of choice for suitable 
patients with solitary renal cell carcinoma ampullary metastasis. A minimally invasive approach may result in early 
recovery of patient to be suitable for subsequent chemotherapy. Further evidence is needed to address the exact 
role of minimally invasive pancreaticoduodenectomy in renal cell carcinoma metastasized to the ampulla of Vater. (Ann 
Hepatobiliary Pancreat Surg 2018;22:83-89)
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INTRODUCTION
Renal cell carcinoma is the most common primary re-
nal neoplasm in adults.1 It accounts for approximately 
2-4% of all adult malignancies.2,3 Surgery may be curative 
if the disease is localized. However, many patients even-
tually experience relapse. The most common metastasis 
sites for renal cell carcinoma are lungs, bones and liver.4 
Although renal cell carcinoma is known to spread to un-
usual sites, the ampulla of Vater is considered a rare 
metastasis site. When this occurs, it may be indistinguish-
able from primary ampullary tumor during initial 
presentation. Interestingly, renal cell carcinoma is not the 
only malignancy known to spread to the ampulla of Vater. 
Melanomas,5,6 breast carcinomas,7,8 squamous cell carci-
noma of the larynx,9 and cervical carcinoma10 can also 
spread to the ampulla of Vater. Despite advances in lapa-
roscopic techniques and experiences, it remains con-
troversial whether laparoscopic pancreaticoduodenectomy 
should be regarded as a safe and effective surgical ap-
proach for selected patients.11 In this case report, we pres-
ent a patient with renal cell carcinoma metastasized to the 
ampulla of Vater who was successfully treated with lapa-
roscopic pancreaticoduodenectomy. To the best of our 
knowledge, this is the first report of laparoscopic pan-
creaticoduodenectomy for renal cell carcinoma metasta-
sized to the ampulla of Vater. We also provided a brief 
literature review.
CASE
Patient description
A 62-year-old Korean male patient presented with jaun-
dice and dark urine in December 2016. He had a history 
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Fig. 1. (A) Endoscopic view showing whitish firm mass from the superior duodenal angle to the ampulla of Vater. (B) 
Preoperative MRI pancreaticobiliary T2 weighted image showing a papillary shaped mass in the ampulla of Vater with duodenal
and pancreas extension. (C) PET-CT showing increased FDG uptake of the tumor involving the duodenum and pancreatic head.
T, tumor.
of hypertension and right-sided renal cell carcinoma diag-
nosed in September 2004, for which he underwent right 
radical nephrectomy in October 2004. Pathological analy-
sis reported a conventional type, Fuhrman nuclear grade 
2 tumor with hemorrhage and sclerosis (T1N0M0). He 
had no known family history of renal malignancy. He did 
not smoke. He did not excessively drink alcohol either.
Preoperative findings
Physical examination did not yield any significant 
findings. Laboratory results showed the following: aspar-
tate transaminase (AST), 169 U/L; alanine transaminase 
(ALT), 213 U/L; total bilirubin, 2.4 mg/dl; gamma glutamyl 
transferase (γ-GT), 992 U/L; lipase, 221 U/L; amylase, 155 
U/L; alkaline phosphatase (ALP), 650 U/L; carcinoem-
bryonic antigen (CEA), 4.21 ng/ml; and cancer antigen 
19-9 (CA19-9), 10.9 U/ml. Magnetic resonance imaging 
(MRI) pancreaticobiliary, positron emission tomog-
raphy-computed tomography (PET-CT), and endoscopic 
retrograde cholangiopancreatography (ERCP) showed a 
firm whitish mass from the duodenum superior duodenal 
angle to the ampulla of Vater (Fig. 1). Endoscopic ultra-
sound-fine needle aspiration (EUS-FNA) cytology analysis 
revealed clusters of atypical pancreaticobiliary epithelial 
cells suspicious for malignancy. The initial impression was 
ampulla of Vater cancer with duodenal and pancreatic 
extension. Differential diagnoses of duodenal cancer or 
pancreatic cancer were also considered.
Operation and pathologic findings
The patient underwent laparoscopic pylorus preserving 
total pancreaticoduodenectomy in January 2017. As a re-
sult of the previous operation, there were severe adhesions 
at retroperitoneum and previous renal vein ligation sites. 
The colon and duodenum were rotated due to the absence 
of the right kidney. It was difficult to dissect the superior 
mesenteric artery (SMA) lateral margin due to adhesion 
after the previous retroperitoneal space dissection. After 
the resection phase, pancreaticojejunostomy (duct-to-mu-
cosa) and hepaticojejunosotmy were done via laparoscopic 
approach. Duodenojejunostomy was done through a small 
mini laparotomy around the umbilicus where surgical 
specimen needed to be removed. Operation time was 510 
min and estimated blood loss was 400 ml. Gross findings 
for the specimen included a protruding mass on the am-
pulla of Vater (Fig. 2). Pathological examination revealed 
metastatic clear cell renal carcinoma involving the duode-
num, ampulla of Vater, and pancreas (Fig. 3). The tumor 
size was 5.4 cm in maximum diameter. Lymphovascular 
invasion was noted without perineural invasion. All re-
section margins including the common bile duct, pancre-
atic duct, duodenum, and retroperitoneum were negative 
for carcinoma cells. Total retrieved lymph nodes were 13 
without any positive nodes.
Postoperative recovery
The length of hospital stay was 12 days postoperatively. 
During hospital stay, there were no significant post-
operative complications. The patient was regularly fol-
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Fig. 2. Operative findings after resection phase. (A) Bile duct was clamped and the gastroduodenal artery (GDA) was ligated. 
(B) Reconstruction phase of laparoscopic pancreaticojejunostomy (duct-to-mucosa). (C) Reconstruction phase of laparoscopic 
hepaticojejunostomy. (D) Specimen gross finding showing the protruding mass on the ampulla of Vater. BD, bile duct; GDA,
gastroduodenal artery; Pan, pancreas; PV, portal vein; J, jejunum; T, tumor; CBD, common bile duct; AoV, ampulla of Vater.
Fig. 3. Pathologic report. (A) Tumor invading the proper duodenum muscle layer (×12.5). (B) Characteristic appearance of renal
clear cell carcinoma with clear cytoplasm arranged in nests (×100). Dm, Duodenum mucosa; BG, Brunner’s gland; Pm, Proper
muscle layer; T, Tumor.
lowed up in Urology and Surgery Outpatient Departments 
to consider adjuvant chemotherapy.
Literature review
Based on literature review, a total of 11 patients with 
renal cell carcinoma metastasized to the ampulla of Vater 
have been reported (Table 1). Nine patients were males 
and three were females. Their mean age was 62.6±11.6 
years. These patients had relatively early stage renal cell 
carcinoma when initial nephrectomy was performed. 
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Table 1. Cases of renal cell carcinoma metastasized to the ampulla of Vater
Case no. Publish year Authors Patient age RCC side Tumor stage on discovery
1
2
3
4
5
6
7
8
9
10
11
12
1989
1990
1991
1991
1996
1996
1998
2010
2013
2014
2014
 
McKenna et al.16
Robertson and Gertler17
Venu et al.18
Bolkier et al.19
Leslie et al.20
Leslie et al.20
Janzen et al.21
Teo et al.22
Karakatsanis et al.25
Haidong et al.23
Chowdhury et al.24
Current case
52/M
70/M
64/M
57/F
78/F
53/M
75/M
50/F
77/M
50/M
Mid-aged/M
62/M
Left
Left
Left
Left
Left
Right
Left
Left
Right
Right
Not mentioned
Right
Stage I
Stage III
Stage I
Stage II
Stage II
Stage III
Not mentioned
Stage II
Stage 2
Stage IV*
Not mentioned
Stage 1
*Metastatic cancer to the ampulla of Vater was discovered at the same time as RCC
RCC, Renal cell carcinoma
Table 2. Summary of specific symptoms, treatment, interval time to recurrence and overall survival in each case
Case no. Presenting symptoms Time from nephrectomy (yrs) Treatment Survival
1
 
 
2
 
3
 
 
4
 
5
 
 
6
 
 
7
 
 
 
8
 
 
9
 
 
 
10
 
11
 
 
12
 
 
Malabsorption
 
 
Melena and weakness
 
Gastrointestinal bleed, 
malaise, fatigue, 
shortness of breath
Obstructive jaundice
 
Upper abdominal 
discomfort, pruritus, 
jaundice, melena
Melena and weight loss
 
 
Gastrointestinal bleed
 
 
 
Obstructive jaundice and 
right upper quadrant 
colicky pain
Fever, malaise, fatigue, 
and jaundice, diarrhea
 
 
Jaundice and cholangitis
 
Painless obstructive 
jaundice
 
Jaundice
 
 
10
 
 
12
 
11
 
 
 2
 
10
 
 
 8
 
 
17.5
 
 
 
 2
 
 
 0*
 
 
 
 6
 
 3
 
 
12
 
 
Palliative procedure: ERCP 
sphincterotomy, 
choledochoduodenostomy
Resectional operation: 
Pancreaticoduodenectomy
Resectional operation: Chemotherapy and 
Pancreaticoduodenectomy for recurrent 
bleeding
Palliative procedure: Percutaneous 
transhepatic stent
Resectional operation: PPPD
 
 
Resectional operation: Pylorus-preserving 
total pancreaticoduodenectomy
 
Resectional operation: Total 
pancreaticoduodenectomy with 
cholecystectomy and splenectomy
 
Palliative procedure: ERCP with biliary 
stent insertion.
 
Resectional operation: Open right radical 
nephrectomy standard 
pancreatoduodenectomy, with systemic 
therapy (IFN-α-2b)
Palliative procedure: Percutaneous 
transhepatic stent.
Palliative procedure: Endoscopic 
ampullectomy, sphincterotomy. Stent 
insertion
Resectional operation: Laparoscopic 
pylorus preserving total 
pancreaticoduodenectomy
Deceased at 1 year due 
to GI haemorrhage
 
Deceased at ＜1 year 
due to lung metastasis
Postop expire due to 
pulmonary embolism
 
Deceased at 2 months 
due to brain metastasis
Alive without evidence 
of recurrent disease at 
2.5 years
Alive with disease at the 
last follow-up 6.5 
years later
Patient was discharged 
home after a 
protracted period of 
convalescence
Deceased 2 months after 
onset of symptoms
 
Alive without evidence 
of disease recurrence 
5 years later
 
Not mentioned
 
The patient succumbed 
to metastatic disease 
1.5 years later
Alive without evidence 
of disease at the time 
of writing
*Metastatic cancer to the ampulla of Vater was discovered at the same time as renal cell cancer
ERCP, endoscopic retrograde cholangiopancreatography; PPPD, pylorus-preserving pancreaticoduodenectomy; IFN, interferon
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Fig. 4. Literature review-based oncologic outcome analysis of patients with metastatic renal cell carcinoma to the ampulla of
Vater. (A) Overall survival between patients who underwent palliative procedures and those who underwent resectional operations.
(B) Overall survival between the two groups of patients according to age. (C) Overall survival between the two groups of patients
according to gender. (D) Overall survival between the two groups of patients according to the interval time from initial neph-
rectomy to diagnosis of metastasis.
Mean time interval from initial nephrectomy to diagnosis 
of metastatic renal cell carcinoma to the ampulla of Vater 
was 82.5±64.9 months. The most common symptom was 
obstructive jaundice. Palliative procedures such as ERCP 
with sphincterotomy, endoscopic ampullectomy, percuta-
neous transhepatic biliary drainage with stent insertion, 
and choledochoduodenostomy were performed in five 
patients. Pancreaticoduodenectomy was performed in sev-
en patients, including the present case (Table 2). Mean 
overall survival time for patients who had metastatic renal 
cell carcinoma to the ampulla of Vater from initial neph-
rectomy was 106.3±57.9 months (95% CI: 72.6-137.8 
months), excluding two cases without mentioning the sur-
vival time. Mean survival after a resection for metastatic 
ampulla of Vater cancer was found to be superior to that 
with palliative management (137±40.1 months vs. 
59.5±50.1 months; p=0.00134). However, there was no 
statistically significant difference in overall survival be-
tween the two groups according to age, gender, or interval 
time from initial nephrectomy to diagnosis of metastasis 
to the ampulla of Vater (Fig. 4).
DISCUSSION
Here we report a patient with right-sided renal cell car-
cinoma metastasized to the ampulla of Vater presenting 
with jaundice 12 years after initial treatment for renal 
malignancy. To the best of our knowledge, this is the first 
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case of renal cell carcinoma metastasized to the ampulla 
of Vater treated with laparoscopic pylorus-preserving total 
pancreaticoduodenectomy among a handful of similar cas-
es reported in the literature. Most patients had left-sided 
renal cell carcinoma. They were middle aged to elderly 
males. Based on our observation, the most common pre-
sentations were obstructive jaundice and gastrointestinal 
bleeding. Other presentations included malabsorption, fa-
tigue, weight loss, abdominal pain/discomfort and re-
current cholangitis.
The mean time from initial nephrectomy to diagnosis 
of metastatic ampulla of Vater cancer was 82.5±64.9 
months. The longest was 210 months. The mean time 
from initial nephrectomy to diagnosis of metastatic ampul-
la of Vater cancer is longer than that for metastases to 
other regions, most of which is within the first two to 
three years following nephrectomy.11 It is known that a 
prolonged interval between nephrectomy and appearance 
of metastasis is associated with better prognosis.12 Based 
on literature review, this trend was seen in most cases, 
but not in all cases. Except for two cases that did not 
mention the overall survival time, patients who underwent 
resectional operation for metastatic ampulla of Vater can-
cer had favorable long-term survival compared to those 
in the palliative management group. However, we could 
not find any statistically significant difference in survival 
according to gender, age, or interval time from initial 
nephrectomy to diagnosis of metastatic lesions. There was 
no association between initial stage of primary disease 
and interval time to recurrence either.
Solitary metastases of renal cell carcinoma have been 
treated successfully by surgical resection, achieving 5-year 
survival rates of 24%-60%.11,13,14 In one study of twelve 
patients who underwent pancreaticoduodenectomy for 
metastatic ampullary and pancreatic tumors, surgical re-
section for solitary metastases of renal cell carcinoma pro-
vided favorable survival rates.15 Based on literature re-
view, most patients who received surgery for solitary 
metastasis to the ampulla of Vater had good post-operative 
survival. Due to the lack of data, we were unable to calcu-
late the exact average survival in number of years. 
Nonetheless, we believe that pancreaticoduodenectomy is 
a treatment choice for suitable patients with solitary am-
pullary metastasis of renal cell carcinoma. Minimally in-
vasive approach may provide patient a potential chance 
for early recovery to be suitable for subsequent 
chemotherapy. Further evidence is needed to address the 
exact role of minimally invasive pancreaticoduodenectomy 
in renal cell carcinoma metastasized to the ampulla of 
Vater.
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